Characterizing MHC-I Genotype Predictive Power for Oncogenic Mutation Probability in Cancer Patients.

Area of Science:

• Immunology and Oncology
• Computational Biology

Background:

• MHC class I proteins present intracellular peptides, including tumor neoantigens, to T cells for immune surveillance.
• Variable peptide-MHC-I affinity affects neoantigen presentation, influencing immune evasion and tumor development.
• Individual MHC-I genotype is a key factor in peptide-MHC-I binding affinity.

Purpose of the Study:

• To develop a residue-centric scoring system to quantify peptide-MHC-I presentation.
• To investigate the correlation between presentation scores and tumor mutation frequencies.
• To explore the potential for personalized cancer therapy based on MHC-I genotype and neoantigen presentation.

Main Methods:

• Developed a residue-centric presentation score considering mutated residues and MHC-I genotype.
• Applied the scoring system to 9176 tumor samples from The Cancer Genome Atlas (TCGA).
• Analyzed 1018 recurrent mutations to assess the predictive power of presentation scores.

Main Results:

• Presentation scores significantly predicted mutation probability across diverse tumor types.
• High presentation scores (indicating poor presentation) correlated with higher tumor mutation frequencies.
• The findings demonstrate a link between MHC-I presentation efficiency and tumor mutational landscape.

Conclusions:

• The developed scoring system effectively predicts neoantigen presentation and its impact on tumor evolution.
• Individual MHC-I genotype plays a crucial role in determining tumor immunogenicity and mutation patterns.
• These findings support the development of personalized cancer treatments informed by genetic profiling.